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Among vaccines aimed at treating substance use disorders, those targeting opioids present
several unique medication development challenges. 1) Opioid overdose is a common compli-
cation of abuse, so it is desirable for an opioid vaccine to block the toxic as well as the addic-
tive effects of opioids. 2) It is important that an opioid vaccine not interfere with the action of
opioid antagonists used to reverse opioid overdose or treat addiction. 3) Some opioids are
immunosuppressive and chronic ongoing opioid use could interfere with vaccine immunoge-
nicity. 4) Although antibody-bound oxycodone is unable to enter the brain because of its size,
it might still be able to activate peripheral opioid receptors. To assess vaccine impact on opi-
oid toxicity, rats vaccinated with oxycodone conjugated to keyhole limpet hemocyanin sub-
unit dimer (OXY-dKLH) adsorbed to alum or controls vaccinated with dKLH were compared
with regard to oxycodone-induced hotplate analgesia and oxycodone-induced respiratory
depression and bradycardia. Vaccination shifted the dose-response curves to the right, rep-
resenting protection, for each of these endpoints. Naloxone was equally effective in both
OXY-dKLH and control groups, providing complete and rapid reversal of respiratory depres-
sion. The administration of a long-acting naltrexone formulation during vaccination did not
impair vaccine immunogenicity in mice. Similarly, serum anti-oxycodone antibody titers were
not altered by continuous morphine infusion during vaccination compared to opioid-naïve
controls. Competitive ELISA assay showed negligible or low affinity of immune antiserum for
endogenous opioids or opioid antagonists. In vitro receptor binding assays showed that anti-
body-bound oxycodone does not activate mu opioid receptors. These data support further
study of OXY-dKLH as a potential treatment for oxycodone abuse and suggest that vaccina-
tion might also reduce the severity of oxycodone overdose.
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Introduction
Vaccines have been studied as potential adjuncts for the treatment of substance use disorders
including nicotine [1], cocaine [2], methamphetamine [3] and opioids [4]. Key to their efficacy
is their ability to elicit high concentrations of high affinity antibodies against those drugs [5,
6]. Vaccines targeting opioids present some unique considerations with regard to their safety
or efficacy. Above and beyond the enormous personal and societal harm of opioid addiction,
opioid abuse is now a leading cause of accidental death in the U.S [7, 8]. This presents a com-
plex clinical setting for the possible use of a vaccine as a treatment strategy.
Opioid vaccines have been developed with the goal of blocking the addictive effects of opi-
oids, most importantly their reinforcing and rewarding properties [4]. Less attention has been
directed at blocking their toxic effects such as respiratory depression, bradycardia, or coma. In
principle a vaccine should block all opioid effects since it acts by binding the targeted opioid
and preventing its distribution to the central nervous system as well as its interaction with opi-
oid receptors. However toxic effects of opioids tend to occur at higher doses than reinforce-
ment or reward, and may to some extent be mediated outside of the central nervous system. It
is therefore important to establish whether opioid vaccines provide protection against opioid
toxicity, most importantly respiratory depression, as well as addiction. If this were not the
case, vaccinated individuals using large doses of oxycodone to get the desired reward might
experience disproportionate respiratory depression.
While the goal of an opioid vaccine is to block opioid agonist effects, it is important to pre-
serve the efficacy of opioid antagonists. Naloxone is widely used both by medical personnel
and bystanders to reverse opioid overdose [9] while naltrexone is an effective treatment option
for opioid use disorder [10]. Because these uses of opioid antagonist are critical it is important
that an opioid vaccine not interfere with their clinical use.
Opioids are well recognized to interact and in some cases interfere with immune responses.
Morphine, the best studied in this regard, has been shown to blunt antibody responses to sev-
eral infectious agents or immunogens in animals [11]. Opioid addicts or those on methadone
maintenance may show mildly reduced titers to hepatitis B and influenza vaccines [12, 13]. It
is unclear to what extent impaired vaccine responses might be due to opioid use per se or to
other conditions common in opioid abusers such as infections or the use of other drugs. Nev-
ertheless it is possible that ongoing opioid use could blunt the generation of antibodies from
an opioid addiction vaccine. If so, this could limit the efficacy of an opioid vaccine or require a
more aggressive vaccination regimen with higher immunogen doses or more booster doses.
Addictive drugs are small molecules and it is assumed that once they bind to antibody they
are sterically hindered from interacting with drug receptors, but this assumption has not been
tested explicitly. Opioids (MW 300–500 Da) are somewhat larger than nicotine, cocaine or
amphetamines (MW 149–303 Da), so it is reasonable to ask whether opioid binding to anti-
body prevents them from activating opioid receptors. In animals, vaccination with heroin or
oxycodone vaccines blocks or attenuates a variety of behaviors that are mediated primarily by
mu opioid receptors (MOR) [14–17]. This argues that binding to antibody prevents opioid
binding to the MOR. However it is difficult to distinguish from these data alone whether com-
plete or partial inhibition of opioid binding to the MOR has occurred. Serum opioid concen-
trations in vaccinated subjects can be quite high because of binding of opioid to the very high
levels of opioid-specific antibody present in serum [18]. It is therefore of interest to assess the
extent to which opioid binding to antibody prevents activation of the MOR.
The current studies in rats and mice addresses these concerns using a well characterized
oxycodone vaccine that has been shown to reduce oxycodone distribution to brain in rodents
and attenuate addiction-relevant behaviors including oxycodone-induced antinociception and
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self-administration [17–19]. The issues addressed in this study are among the most important
challenges posed by the development of opioid vaccines.
Materials and methods
Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocols were
approved by the Minneapolis Medical Research Foundation Animal Care and Use Committee.
All surgery was performed under isoflurane anesthesia, animals were euthanized by CO2 inhala-
tion using AAALAC approved chambers, and all efforts were made to minimize suffering.
Animals
Male Holtzman rats (Envigo, Madison, WI) weighing 200–225 g were double housed with 12/
12-hour standard light/dark cycle. Male BALB/c mice (Envigo, Madison, WI) 5–6 weeks old were
housed in groups of 4 under 12/12-hour standard light/dark cycle. Rats were used for most studies
because oxycodone vaccine effects have been most extensively studied in this species. Mice were
used for the morphine immunosuppression experiment because this model is well established in
mice [20]. Mice were used for the naltrexone immunosuppression experiment because naltrexone
at a similar dose has been shown to produce sustained analgesia in mice [21, 22].
Vaccines and drugs
Mice were immunized with OXY-KLH consisting of oxycodone attached to a tetraglycine linker
at the C6 position, conjugated through the linker’s carboxyl terminus to the carrier protein key-
hole limpet hemocyanin (KLH) [18]. This immunogen was adsorbed to aluminum hydroxide
(Alhydrogel, Invitrogen, San Diego, CA) and administered at a dose of 25 μg. Immunization
with OXY-KLH vaccine generates high serum concentrations (300–800 μg/ml) of oxycodone-
specific antibodies in mice or rats [17–19, 23]. Native KLH is a large protein of molecular weight
5,000–8,000 kDa consisting primarily of decamers and didecamers of 440 kDa subunits [24].
Vaccine studies involving mice used native KLH as the carrier. To facilitate formulation and
analysis of the product, subsequent studies involving rats used immunogen conjugated to GMP
KLH subunit dimer (dKLH, Stellar Bioechnologies, Port Hueneme, CA) administered at a dose
of 60 ug. The KLH and dKLH conjugates are comparably immunogenic and produce similar
serum concentrations of oxycodone-specific antibodies and effects on oxycodone distribution
in mice or rats [23]. Control vaccine consisted of carrier protein adsorbed to alum.
Oxycodone HCl (NIDA Drug Supply Program) was administered in 0.9% NaCl. Serum
and brain oxycodone concentrations were measured by gas chromatography-mass spectro-
photometry as previously described, and all doses and concentrations are expressed as weight
of the base. Brain oxycodone concentrations were corrected for brain blood content [18].
General cell culture reagents were obtained from Life Technologies Corporation or
Hyclone Laboratories, Inc. (South Logan, UT). Oxycodone-specific murine monoclonal anti-
body (OXY-specific mAb) was obtained from MyBioSource (San Diego, CA) with a stated
purity of 95%.
Immunologic assays
ELISA. Serum oxycodone-specific IgG antibody titers were measured by enzyme linked
immunoassays (ELISA) with oxycodone conjugated to BSA (OXY-BSA) as the coating antigen.
OXY-BSA was diluted in 0.05 M carbonite buffer pH 9.6, coated onto Costar 9018 EIA/RIA 96
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well polystyrene plates (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), and
stored overnight at 4˚C. Plates were washed 5 times with 0.05 phosphate buffered saline
tween-20 pH 7.2–7.4 (PBST) and repeated between all steps in the ELISA. Plates were blocked
with 1% gelatin in PBST for 1 h at room temperature, washed, and stored overnight at 4˚C.
The next day various dilutions of sera in 0.05 M PBST were added to the wells and plates incu-
bated for 2 h at room temperature. The secondary (detecting) antibodies, Fc-specific goat anti-
rat or anti-mouse IgG coupled to horseradish peroxidase (Jackson ImmunoResearch Labora-
tories, Inc., West Grove, PA), were diluted in 0.05 M PBST, added to the wells, and incubated
at overnight at 4˚C. The following day enzyme substrate o-phenylenediamine (OPD) was used
(SIGMAFASTTM tablet set, Sigma Life Sciences, St Louis, MO). After 30 min of incubation in
the wells, 2% oxalic acid was added to stop the enzymatic reaction. Plates were read at 492 nm
on a BioTek PowerWave XS (BioTek Instruments Inc., Winooski, VT). Titers were estimated
as the dilution producing 50% maximal binding [18].
Competition ELISA. The relative affinities of various drugs for serum oxycodone-specific
antibodies were measured by competition ELISA, which differs from the above ELISA assay in
two ways. 1) Serum titers measured using ELISA described above was diluted to a fixed 70%
maximal binding in the absence of competitor and 2) mixed with competitors that ranged in
concentrations from 10−2 M to 10−11 M diluted in 0.9% NaCl. Relative affinity was determined
as the concentration of competitor that reduced the binding of serum antibodies to the plate
by 50% and were expressed as the IC50 concentration for oxycodone divided by the IC50 con-
centration for the competitor x 100.
hMOR calcium mobilization assay
The ability of an oxycodone monoclonal antibody (OXY-mAb) to selectively inhibit μ opioid
receptor activation by oxycodone was assessed using CHO cells overexpressing both Gα16, a pro-
miscuous G protein, and the human μ opioid receptor. An OXY-specific mAb was used rather
than antiserum generated by the OXY-dKLH vaccine because serum interfered with the assay, as
did protein G-purified IgG. The day before assay, wells were seeded (30,000 cells/well) in 96-well,
black clear-bottom tissue culture-treated plates (Corning Life Sciences, Tewksbury, MA) and incu-
bated (37˚C; 5% CO2) overnight. On the day of assay, the cells were washed once with assay buffer
(1X HBSS; 0.02M HEPES; 0.781 mg/mL probenecid; 37˚C; pH 7.4; Life Technologies Corporation,
Grand Island, NY) and incubated for 1 hr at 37˚C with 200 μl of half the recommended concentra-
tion of Calcium 5 dye (Molecular Devices, Sunnydale, CA). Either the μ opioid agonist oxycodone
(10 mM; 100% DMSO) or morphine (10 mM; 100% DMSO) were incubated (30 min; RT) ±Ab
(4.38 mg/ml; PBS; MyBioSource, San Diego, CA) at 5x their respective final assay concentrations
of 1 μM (EC50), 50 nM (EC50), and 1:20 dilution. Dubelccos PBS was used for all dilution steps and
the final assay DMSO concentration of 1%. At assay, the 96-well plate was placed in a FlexstationII
(Molecular Devices) and 50 μl of oxycodone-specific murine monocolonal antibody (OXY-mAb)
in duplicate was added to each well at a final concentration of 3 μM and fluorescence intensity
recorded (26 read/sec; 60 sec). Peak relative fluorescence units were used to determine the maxi-
mum response. Data were graphed using Prism (v7; GraphPad, San Diego, CA).
Antinociception and respiratory depression
Groups of 16 rats were immunized with OXY-dKLH or control dKLH vaccine containing
60 μg immunogen and 90 μg aluminum as Alhydrogel. Vaccine was administered intramuscu-
larly every 3 weeks for a total of 4 doses. One week after the final vaccine dose baseline antino-
ciception (prior to oxycodone administration) was assessed by placing rats on a 54˚C hotplate
and measuring the latency to respond, defined as the time until a response of hindpaw lick or
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jumping [18]. Trials were terminated at 60 sec if rats had not responded. Immediately follow-
ing the hotplate trial a MouseOx (STARR Life Sciences Corp., Oakmont, PA) arterial oxygen
saturation (SaO2) monitor was placed via neck collar and baseline SaO2 was measured. Rats
then received oxycodone every 17 minutes s.c. so that their cumulative oxycodone dose at suc-
cessive intervals was 1.1, 2.2, 4.5 and 9.0 mg/kg. This oxycodone dose range produced a wide
range of antinociception, and the 9.0 mg/kg dose was the highest that could be administered
without producing excessive respiratory depression. Fifteen minutes after each oxycodone
dose antinociception and SaO2 was again measured; this took 2 minutes, resulting in the 17
minutes oxycodone dosing interval. Heart rate was obtained from the oximeter.
Naloxone reversal of opioid effects
In the antinociception and respiratory depression experiment described above, rats received
0.1 mg/kg naloxone s.c. immediately after the final antinociception and SaO2 measures were
obtained. Antinociception and cutaneous SaO2 were again measured 15 min after naloxone
administration. The naloxone dose was chosen based on pilot data indicating that a s.c. dose of
0.01 mg/kg naloxone was not sufficient to reliably reverse oxycodone toxicity in non-vacci-
nated rats receiving oxycodone 9.0 mg/kg. For perspective, the 0.01 mg/kg naloxone is compa-
rable to the initial naloxone dose used to reverse opioid overdose in humans, and 0.1 mg/kg is
comparable to the maximum recommended dose [25].
To determine the rapidity with which naloxone reversed oxycodone respiratory depression,
one week after the above experiment the same rats received a single oxycodone dose of 9.0 mg/
kg. Thirty minutes later each rat received 0.1 mg/kg naloxone s.c. Arterial SaO2 was measured
1 minute before and for 3 minutes after naloxone administration.
Vaccine immunogenicity with concurrent morphine infusion
Two groups of 12 mice were anesthetized and Alzet1 s.c. pumps (model 2006) were placed
for morphine or saline infusion. Mice were used because the immunosuppressive effects of
morphine are more thoroughly documented for mice than for rats. Morphine or an equivalent
volume of saline was delivered at a rate of 8 mg/kg daily, as calculated from the morphine solu-
tion remaining in the pump when removed. One week after placement of the s.c. pump both
groups of mice were vaccinated s.c. with OXY-KLH 25 μg and 250 μg aluminum as Alhydro-
gel. A total of 3 vaccine doses were administered at 2 week intervals. Serum was obtained one
week after each vaccine dose for measurement of oxycodone-specific antibody titers.
Vaccine immunogenicity with concurrent naltrexone dosing
Two groups of 7 BALB/c mice received extended-release naltrexone (Vivitrol 1) 50 mg/kg i.
m. or saline once on day 0. Both groups were then vaccinated with s.c. OXY-KLH 25 ug/kg in
alum every 2 weeks for a total of 3 vaccine doses. Oxycodone-specific antibody titers were
measured 1 week after the final vaccine dose and over the following 60 days.
Data analysis
Latency to respond in the hotplate nociception test, SaO2 and serum antibody titers were com-
pared between groups over time by 2-way ANOVA using Sidak’s multiple comparisons test.
The effect of naloxone on latency to respond or SaO2 within a single group used a two sided
paired t test with values before and after naloxone. For the naltrexone/OXY-KLH vaccine
experiment, multiple t tests were used rather than ANOVA because of 3 missing data points.
All statistics were performed using Prism (v7; GraphPad, San Diego, CA).
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Results
Vaccine effects on oxycodone-induced antinociception, respiratory
depression, and heart rate
Serum oxycodone-specific antibody titers on days 14, 28, 49, 70 (2 weeks after the first vaccine
dose and 1 week after the subsequent vaccine doses) were 54 ± 12, 90 ± 34, 156 ± 64, and
148 ± 85 x 103 respectively (mean±SD). Hotplate antinociception as measured by latency to
respond was comparable between groups prior to opioid administration (Fig 1A). The dose-
response curve for latency after increasing cumulative doses of oxycodone was shifted to the
right by vaccination with OXY-dKLH indicating attenuation of oxycodone-induced antinoci-
ception (vaccination, F(1,29) = 7.40, p< 0.05; interaction, F(5,145) = 4.41, p< 0.001; oxyco-
done dose, F(5,145) = 112.6, p< 0.001). Groups differed in mean latency after the 1.1 and 2.2
mg/kg cumulative oxycodone doses. They did not differ after the higher doses but latency is
capped at 60 sec by removal of animals from the hotplate, so that differences might not be
demonstrable.
Respiratory adequacy as measured by SaO2 was comparable between groups prior to opioid
administration (Fig 1B). As with antinociception, the dose-response curve for SaO2 was shifted
to the right by OXY-dKLH indicating attenuation of respiratory depression (vaccination, F
(1,29) = 14.97, p< 0.001; interaction, F(5,145) = 8.13, p< 0.001; oxycodone dose, F(5,145) =
147.5, p< 0.001). Groups differed in mean SaO2 after the 2.2 and 4.5 mg/kg oxycodone doses
but not at the highest 9.0 mg/kg dose.
Heart rate was comparable between groups prior to opioid administration (Fig 1C). Heart
rate was significantly higher in the OXY-dKLH group after the 2.25 mg/kg oxycodone dose,
and numerically but not significantly higher at all other times (vaccination, F(1,29) = 11.06, p
<0.01; interaction, F(5,145) = 1.66, p = 0.15; oxycodone dose, F(5,145) = 56.59, p< 0.001).
Naloxone reversal of oxycodone effects
Hotplate antinociception and respiratory depression were completely reversed in both the
OXY-dKLH and control vaccine groups by administration of naloxone (Fig 1A and 1B). Both
groups showed a significant change toward baseline in these measures after naloxone, and
there was no significant difference between groups after naloxone administration. Heart rate
was restored to near baseline in both OXY-dKLH and control vaccine groups after naloxone
administration (Fig 1C).
The rate at which naloxone reversed oxycodone-induced respiratory depression was stud-
ied one week later. Rats received a single oxycodone dose of 9.0 mg/kg followed in 30 min by
0.1 mg/kg naloxone. Recovery of SaO2 did not differ between OXY-dKLH and control groups,
with essentially complete return to baseline and comparable SaO2 values within 3 minutes of
receiving naloxone (Fig 2).
Vaccine immunogenicity during concurrent morphine infusion
To assure that the dose of morphine that mice received in this protocol was clinically relevant,
antinociception was tested 1 week after s.c. morphine pump placement (prior to vaccination).
The morphine pump group showed a significant increase in latency to respond (t = 2.215,
p< 0.05, Fig 3A). Vaccination was initiated after hotplate testing, with vaccine administered
on days 0, 14 and 28. Oxycodone-specific IgG antibody titers measured 1 week after each vac-
cine dose did not differ between OXY-KLH and control KLH groups (t = 0.72, p = 0.48, Fig
3B).
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Vaccination during concurrent naltrexone administration
The administration of extended-release naltrexone to mice did not alter their response to vac-
cination. Oxycodone-specific titers in serum did not differ between naltrexone and control
groups at any time after completion of vaccination (p at all time points> 0.1, Fig 4).
hMOR-mediated calcium mobilization assay
At an OXY-mAb:oxycodone molar ratio of 3:1, OXY-specific mAb abolished oxycodone-stim-
ulated calcium mobilization (Fig 5). Morphine-stimulated calcium mobilization of MOR was
not inhibited by OXY-specific mAb, showing the antibody’s specificity for binding oxycodone.
OXY-dKLH specificity
The relative affinities of antibodies elicited by vaccination of rats with OXY-dKLH, measured
by competition ELISA, showed high specificity (high cross-reactivity) for oxycodone and its
active metabolite oxymorphone, and low or no measurable cross-reactivity for endogenous
opioids, naloxone or naltrexone (Table 1).
Discussion
Several medication treatments for opioid addiction are available and in clinical use. Metha-
done, buprenorphine and naltrexone have each shown efficacy in reducing illicit opioid use
and its consequences [26]. Despite their efficacy, each has potential drawbacks, side effects,
legal constraints to prescribing, or social stigma associated with their use [27–29]. The result is
that many opioid addicts or abusers who might benefit from these medications find them
unappealing or unsatisfactory and are not using them [30, 31]. Additional alternative medica-
tions that avoid some of these limitations could be helpful in engaging more opioid addicts in
treatment.
Opioid vaccines have been developed but none have been administered to humans, with
the exception of a heroin vaccine studied in Iran but only sparingly described [32, 33]. How-
ever vaccines for nicotine and cocaine have advanced to late stage clinical trails [5]. Their effi-
cacy has to date been limited, most likely due to the moderate and variable titers of antibodies
achieved, but their safety has been repeatedly confirmed [34–36]. Adverse effects have been
minor and limited to reactogenicity, i.e. short-term effects immediately following vaccination
such as soreness at the injection site or mild and short-lived systemic symptoms (aches, mal-
aise) comparable to those observed after other widely used vaccines. This experience confirms
abundant animal data and argues for the general safety of vaccination as a strategy for treating
drug addiction.
The particular aspects of oxycodone vaccine safety and efficacy analyzed in the current
study were chosen based on differences in the actions of opioids compared to nicotine or
cocaine, or the clinical setting in which these drugs are used. Each of these challenges must be
Fig 1. Vaccination inhibits oxycodone-induced antinociception, respiratory depression, and brady-
cardia. Oxycodone was administered s.c. every 15 min at increasing doses and the doses listed are the
cumulative dose received. A) Vaccine effects on oxycodone-induced antinociception. Latency to respond is
capped at 60 seconds. Naloxone was administered 15 min after the final oxycodone dose. B) Vaccine effects
on oxycodone-induced respiratory depression measured as SaO2. C) Vaccine effects on oxycodone-induced
decreases in heart rate. * p < 0.05, ** p < 0.01, *** p < 0.001 for the difference between OXY-dKLH and
control groups. ## p < 0.01 for the difference (within a single group) between values measured after the 9.0
mg/kg oxycodone dose and after naloxone. There were no differences between groups in latency to respond,
SaO2, or heart rate following naloxone treatment. Mean ± SEM; n = 15 for KLH and n = 16 for OXY-KLH.
https://doi.org/10.1371/journal.pone.0184876.g001
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addressed and understood in order to determine whether opioid vaccines should be consid-
ered for clinical trials.
In the current study and others evaluating potential opioid vaccines, hotplate nociception
was used as a surrogate for drug reward because it is mediated in the central nervous system
and provides a relevant behavioral model of the vaccine’s ability to reduce drug access to
brain and its subsequent effects [37]. OXY-dKLH has been shown previously to attenuate
Fig 2. Naloxone reverses oxycodone-induced respiratory depression in vaccinated animals. Naloxone 0.1 mg/kg s.c. was administered
to mice 30 minutes after oxycodone 9.0 mg/kg s.c. SaO2 recovered promptly in both OXY-dKLH and control groups. SaO2 did not differ between
OXY-dKLH and control groups at any time after naloxone treatment (p = 0.65). Mean ± SEM; n = 11 for KLH and n = 12 for OXY-KLH.
https://doi.org/10.1371/journal.pone.0184876.g002
Safety and efficacy of an oxycodone vaccine
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Fig 3. Concurrent morphine administration does not interfere with oxycodone vaccine immuno-
genicity. A) Prior to vaccination, mice receiving s.c. morphine infusion (8 mg/kg/day) showed a significant
increase in latency to respond in the hotplate antinociception test (mean ± SEM, *p <0.05). This confirms that
mice received a behaviorally active dose of morphine for the following experiment: B) After initiation of
vaccination, oxycodone-specific antibody titers in serum did not differ between mice receiving morphine
Safety and efficacy of an oxycodone vaccine
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oxycodone-induced hotplate antinociception [23]. In the current study, OXY-dKLH also
clearly attenuated oxycodone-induced respiratory depression, the predominant cause of death
from opioid overdose. Attenuation of respiratory depression was not evident at the highest
oxycodone dose, as could be anticipated since it is possible to surmount the effects of this or
any other addiction vaccine if the drug dose is sufficiently large. However, the 9.0 mg/kg
cumulative oxycodone dose administered is quite large compared to typically abused human
intravenous doses, reported to range from approximately 0.15 to 1.1 mg/kg [38, 39]. The pro-
tective effect of vaccination at the lower, but still appreciable cumulative oxycodone doses
infusion (8 mg/kg/day) and those receiving saline (mean ± SD, p = 0.51). For both figures, n = 13 for saline-
treated group and n = 12 for morphine-treated group.
https://doi.org/10.1371/journal.pone.0184876.g003
Fig 4. Concurrent administration of extended-release naltrexone does not interfere with oxycodone vaccine immunogenicity.
Mice received 50 mg/kg naltrexone i.m. on day -1 and then vaccinated with OXY-KLH on days 0, 14 and 28. Serum oxycodone-specific
antibody titers did not differ between groups at any time after completion of vaccination (p = 0.21). Mean ± SEM, n = 4–7/group.
https://doi.org/10.1371/journal.pone.0184876.g004
Safety and efficacy of an oxycodone vaccine
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argues that vaccination with OXY-dKLH, while not insurmountable, should provide a sub-
stantial measure of protection against oxycodone overdose. These results are supported by a
study using an oxycodone vaccine with an alternative design that placed the linker at the
bridge nitrogen and used tetanus toxoid as a carrier[40]. This vaccine also produced a right-
ward shift in the hotplate analgesia assay dose-response curve. This shift was larger than in the
current study but it was obtained using mice vaccinated via the intraperitoneal i.p. route,
which would not be used in humans. When vaccination was administered s.c. the observed
reduction in analgesia was comparable to that reported here. A reduction in mortality after
very high doses of oxycodone was reported in mice. These data lend general support to the
Fig 5. Oxycodone-specific monoclonal antibody prevents oxycodone-induced activation of opioid receptors. OXY-specific mAb blocked OXY-
stimulated calcium mobilization but did not block morphine-stimulated calcium mobilization. ***P < 0.001 compared to OXY. Bars represent the % EC50
compared to oxycodone alone (left) or morphine alone (right). Mean ± SEM, n = 3/group.
https://doi.org/10.1371/journal.pone.0184876.g005
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current findings and the ability of vaccination to reduce oxycodone toxicity. Reduced mortal-
ity from fentanyl in mice immunized with a fentanyl vaccine has also been reported [41].
The finding that OXY-dKLH reduces key measures of oxycodone toxicity is also consistent
with results of studies with immunotherapies against methamphetamine [42, 43], nicotine [44,
45] and cocaine [46]. Blockade or reduction of seizures, hypertension, hyperactivity, stereo-
typic behavior and mortality have all been reported. Although some of these studies used pas-
sive immunization rather than vaccination, which can produce higher antibody levels than
vaccines, these data taken together provide support for the ability of immunotherapies to also
provide protection against clinically important toxic drug effects.
A potential concern with this therapeutic approach is that someone vaccinated with OXY-
dKLH might deliberately use more than their usual dose of oxycodone to overcome blockade
of its effects, but then suffer respiratory depression if the vaccine protects less well against
respiratory depression than against the euphoria. Control rats reached 60 seconds latency in
the hotplate assay at an oxycodone dose of 2.25 mg/kg while OXY-dKLH rats required 4.5 mg/
kg. At these equianalgesic doses the two groups had essentially identical SaO2 values of about
87%. The same observation holds true for equianalgesic doses associated with 40 seconds
latency; the extent of respiratory depression was the same between groups. These data show
that, compared to controls, vaccination with OXY-dKLH reduces oxycodone-induced respira-
tory depression in proportion to how much it inhibits antinociception, at least over the oxyco-
done dose range studied. If antinociception is taken as a surrogate for reward, the data suggest
that a vaccinated subject using more than their usual dose of oxycodone in order to obtain
euphoric effects would suffer no more respiratory depression than they would for the equiva-
lent euphoric effect (from a smaller oxycodone dose) before they were vaccinated. Effects of
OXY-dKLH on heart rate were less prominent but also generally protective and support the
conclusion that OXY-dKLH attenuates the most dangerous physiological effects of high doses
of oxycodone.
The specificity of antibodies generated by OXY-dKLH for oxycodone has been reported
previously [18]. In the previous study, the IC50 value for oxycodone was lower than in the cur-
rent study, likely due to the use of a different coating antigen in the ELISA assay. Both the cur-
rent a previous study found similar high cross-reactivity of antiserum with oxymorphone, and
very low cross reactivity with methadone, buprenorphine, and opioid antagonists. Here we
extend ELISA competition evaluation showing no measurable binding of antibody to
Table 1. Relative affinities of antibodies generated by vaccination of rats with OXY-dKLH as mea-
sured by IC50 values in competitive ELISA.










Dynorphin 1–13 1860 –
To estimate relative affinities (cross-reactivity), IC50 values were normalized to that of oxycodone, which is
taken to be 100%. Omitted IC50 concentrations are >10,000 μM and omitted IC50% values are <0.1.
https://doi.org/10.1371/journal.pone.0184876.t001
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endogenous opioids. In addition, naloxone completely reversed oxycodone-induced hotplate
antinociception and respiratory depression in vaccinated rats, showing that the efficacy of this
antagonist for treating clinical opioid overdose is not impaired by vaccination with OXY-
dKLH. Both the extent and the rate of reversal of respiratory depression by naloxone were
fully preserved in rats vaccinated with OXY-dKLH and were similar to those of controls.
Although no saline control was used in the reversal experiment, the complete reversal of respi-
ratory depression occurring within 1–3 minutes of naloxone administration makes spontane-
ous recovery extremely unlikely. In view of the substantial and increasing incidence of opioid
overdose, and the widespread use of naloxone to treat opioid overdose, the non-interference of
OXY-dKLH in this regard is absolutely requisite for considering it as a treatment option.
Additionally, an extended-release (30 day) naltrexone formulation used clinically for the
treatment of opioid abuse did not interfere with the immunogenicity of OXY-KLH in mice.
This result suggests that subjects switching from naltrexone to vaccine or vice-versa for treat-
ment of opioid abuse could do so without interference or the need to stop one before starting
the other. It is known that subjects discontinuing naltrexone face a period of high risk for opi-
oid use and also overdose [10, 47]. It is possible that an opioid vaccine could find application
in offering some degree of protection during this high-risk period.
The potential for opioids to suppress the immunogenicity of infectious disease vaccines has
received some study in humans although most data are observational, and it has been difficult
to determine whether the mildly impaired immunogenicity reported in some, but not all,
groups of opioid users is due to their drug use or their general health or life style [12, 13, 48].
In the current study morphine was administered to mice by chronic s.c. infusion at a dose
within the range of heroin doses that humans might abuse [49] and which has been previously
reported to suppress some aspects of immunity in mice [11, 20] or their immune response to
injury [50]. We used morphine rather than heroin for this experiment because morphine’s sta-
bility is better suited to s.c. pump delivery, and because immunosuppression has been better
studied and demonstrated in rodents for morphine. Oxycodone was not used because it has
not been well studied in this context to determine whether it is immunosuppressive. No sup-
pression of OXY-KLH vaccine immunogenicity by continuous morphine infusion was
observed. These data argue against the possibility that chronic or ongoing opioid use would
impair oxycodone vaccine immunogenicity.
The question of whether antibody-bound oxycodone can still activate opioid receptors was
addressed using an hMOR-mediated calcium mobilization assay. Monoclonal anti-oxycodone
antibody was shown to completely block MOR activation by this measure. A commercially
available mAb was studied rather than antiserum from immunized rats because serum was
found to interfere with the assay. However the commercial mAb binds in ELISA to oxycodone-
protein conjugates synthesized from the same hapten used to immunize rats. It is therefore
likely that the commercial mAb and antibodies from vaccinated rats bind similar oxycodone
epitopes. These data support physiologic data from in vivo studies showing that the very high
concentrations of antibody-bound oxycodone present in the serum of vaccinated animals are
inactive [13–17].
A limitation of this study is that mice were vaccinated with a native KLH conjugate while
rats were vaccinated with a dKLH subunit dimer conjugate. However the close relationship of
these proteins, which differ only in their average degree of aggregation, and their essentially
indistinguishable immunogenicity and effects in both mice and rats [23], suggests that the
results of the current study generalize to both formulations.
Advancement of OXY-dKLH or any other opioid vaccine to clinical trials remains a com-
plex task. It is recognized that an oxycodone vaccine would face additional challenges in clini-
cal use, as it blocks the effects of only oxycodone and its active metabolite, and possibly
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hydrocodone [19]. Prescription opioids, principally oxycodone, are responsible for approxi-
mately half of opioid overdose deaths in the U.S. [51] but some users switch to other opioids
such as heroin when prescription opioid availability is limited and may also be exposed to
other opioids used as adulterants. We have previously reported that concurrent immunization
with oxycodone and heroin vaccines can block the distribution to brain of both classes of opi-
oids or their active metabolites [52]. It is likely that the eventual clinical use of an oxycodone
vaccine such as OXY-dKLH would be as part of such a multivalent vaccine that can target a
wider range of abused opioids.
The favorable safety and efficacy data demonstrated in this study for OXY-dKLH support
its further development as an additional treatment option for oxycodone abuse. Clinical expe-
rience with addiction vaccines, and opioid vaccines in particular, is limited. Studies of these
vaccines in early phase clinical trials, including clinical laboratory studies to examine their abil-
ity to block opioid effects in a controlled setting, are clearly needed to assess the potential of
this strategy as an adjunct to the treatment of opioid use disorder. The high prevalence of opi-
oid use disorder [8] makes the OXY-dKLH vaccine an attractive candidate for further
development.
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